Search the Newsreel

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones

Pyxis Oncology (Nasdaq: PYXS) reported its second-quarter 2026 financial results, highlighting progress in its MICVO clinical development programs and an extended cash runway into Q2 2027 following a $114 million private placement. The company is set to release updated data from the MICVO Phase …

Why is Cullinan Oncology stock surging today? By Investing.com

Brand Concepts Q1 Results: Net loss widens 280% QoQ to ₹290 lakh

Anhui Conch Cement Schedules Board Meeting to Review 2026 Interim Results and Dividend

Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri

Citius Oncology, a biopharmaceutical company, announced the appointment of Jonathan Peri, Ph.D., J.D., as an independent director to its Board, expanding it to nine members. Dr. Peri brings extensive leadership experience in higher education, financial services, law, and corporate governance, which is expected to …

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. Report Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 Rezilient3 Trial in First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for zipalertinib combined with chemotherapy in first-line EGFR exon 20 insertion mutation non-small cell lung …

Cullinan, Taiho's Zipalertinib - Chemotherapy Combo Meets Key Goal In Phase 3 NSCLC Trial; Stock Up

(RTTNews) - Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (CGEM) announced that the Phase 3 REZILIENT3 trial, evaluating the combination of zipalertinib and platinum-based chemotherapy in the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), met …

Once upon a Farm chief accounting officer Chris Folena sells $13,039 in stock

Once Upon a Farm's Chief Accounting Officer, Chris Folena, sold 724 shares of company stock for $13,039 to cover tax obligations. Following the sale, Folena retains 12,724 shares. The company's stock is currently trading below the sale price, and InvestingPro analysis suggests it may …

Once upon a farm chief innovation officer sells $1,350 in shares

Cassandra Nicole Curtis, Chief Innovation Officer and Director at Once Upon a Farm, PBC (NASDAQ: OFRM), sold 75 shares of common stock for $1,350 to cover tax withholding obligations. This transaction leaves Ms. Curtis with 432,908 shares. The company recently reported strong Q2 sales …

Chris Folena Sells 724 Shares of Once Upon A Farm (NYSE:OFRM) Stock

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing …

Oncolytics Biotech (NASDAQ:ONCY) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Oncolytics Biotech (NASDAQ:ONCY) reported a quarterly loss of $0.08 per share, missing analysts' consensus estimate of a $0.05 loss by $0.03. Despite the earnings miss, the stock rose 0.5% to $0.82, and institutional investors have been increasing their holdings. Analysts currently rate the stock …

Once Upon a Farm (OFRM) CFO sells 1,206 shares to cover RSU tax

Once Upon a Farm, PBC's CFO, Lawrence Steven Waldman, sold 1,206 shares of common stock at $18.01 per share on August 10, 2026. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Waldman …

Treace Medical Concepts (TMCI) officer disposes shares for tax or exercise costs

Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts (TMCI), reported a Form 4 transaction indicating the disposition of 9,814 shares of common stock. These shares were delivered or withheld to cover exercise price or tax liability. Following this transaction, Scanlan directly holds …

Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains

Kura Oncology reported strong Q2 2026 results, exceeding Wall Street expectations due to robust early sales of its new cancer drug KOMZIFTI. The company posted a smaller-than-expected loss and higher revenue, driven by KOMZIFTI capturing a majority share of new patient starts in the …

Kura Oncology (NASDAQ:KURA) Issues Earnings Results

CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise

An insider at CG Oncology, Ambaw Bellete, has filed to sell 32,137 common shares of CGON through Morgan Stanley Smith Barney LLC. This proposed sale is linked to a stock option exercise on August 12, 2026, with an aggregate market value of over $2.5 …

Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates

Kura Oncology (KURA) reported a Q2 loss of $0.77 per share, beating the Zacks Consensus Estimate of a $0.89 loss, and revenues of $20.87 million, surpassing estimates by 23.61%. Despite underperforming the S&P 500 year-to-date, the stock holds a Zacks Rank #2 (Buy) due …

Kura Oncology Reports Second Quarter 2026 Financial Results

Kura Oncology announced its second quarter 2026 financial results, highlighting strong commercial performance for its drug KOMZIFTI® (ziftomenib), which generated $9.1 million in net product revenue and achieved a majority share of new patient starts in its class. The company also provided updates on …

Treace Medical Concepts (TMCI) CFO uses 37,102 shares to cover equity-related taxes

Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake

John T. Treace, CEO of Treace Medical Concepts, has filed an amended Schedule 13G indicating a 19.2% beneficial ownership stake in the company, totaling 12,530,959 shares. This ownership includes direct holdings, shares in family trusts, his spouse's holdings, and stock options exercisable within 60 …

ONCY: Net loss increased to $9.4M in Q2 2026, with cash needs exceeding current resources

Oncolytics Biotech Inc. (ONCY) reported a widened net loss of $9.4 million in Q2 2026, attributed to rising R&D and G&A expenses due to clinical trial expansion and increased stock-based compensation. While current cash is sufficient for near-term milestones, the company will require additional …

Kura Oncology: Q2 Earnings Snapshot

Kura Oncology (KURA) grows revenue to $39.1M but widens net loss

Why is Neonc Technologies stock surging today?

Neonc Technologies Holdings Inc. stock surged 11.3% in pre-open trading after its Phase 2a NEO100-01 study met its primary endpoint with a statistically significant six-month progression-free survival rate. The surge was amplified by the stock trading near its 52-week low, a tight float, high …

Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M

Kura Oncology, Inc. (KURA) reported Q2 revenue of $20.9 million, surpassing FactSet's estimated $20.2 million. This earnings flash indicates a positive revenue surprise for the biotechnology and medical research company. The report also mentions other recent financial news, including a widened Q2 diluted loss …

Concentra Group Holdings Parent (CON) Following Earnings And Guidance Lift Through A Valuation Lens

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Concentra Group Holdings Parent (CON) has given investors a cluster of fresh information in August 2026, including second quarter earnings, new full year …

NeOnc Technologies Holdings, Inc. Common Stock (NASDAQ: NTHI) Stock Price, News & Analysis

This article provides an overview of NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) stock, including its current price, daily range, and trading volume. It also lists key fundamental data such as previous close, market cap, and P/E ratio, while noting several financial metrics are currently …

China Conch Environment Sets August Board Meeting to Review Interim Results and Dividend

NeOnc Technologies Holdings Reports Positive Phase 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies Holdings announced positive Phase 2a results for its intranasal NEO100 therapy in recurrent IDH1-mutant high-grade glioma, showing a six-month progression-free survival rate of 48.9%, significantly exceeding the 20% benchmark. The study also reported a median overall survival of 26.09 months and a …

Cardiff Loss Narrows In Q2; Directs Resources To Phase 3 For Onvansertib In Q1 '27

(RTTNews) - Cardiff Oncology, Inc. (CRDF) a clinical-stage oncology company, reported second quarter results, reflecting a narrower loss primarily driven by lower operating expenses. The company in particular noted reduced Research and Development (R&D) expenses following the completion of clinical trials and lesser preclinical …

NeOnc Technologies Reports Positive Phase 2a NEO100 Results; Median OS 26.09 Months, PFS-6 48.9%

NeOnc Technologies reported positive topline results from its Phase 2a study of intranasal NEO100, showing a median overall survival of 26.09 months and a six-month progression-free survival (PFS-6) of 48.9%, significantly exceeding the 20% protocol benchmark. The treatment was well tolerated with low-grade adverse …

Concord Enviro Systems Q2 Results: Earnings call held on Aug 12

Form 8K Citius Oncology Inc For: 12 August By Investing.com

This article announces the filing of a Form 8K by Citius Oncology Inc. on August 12, 2026. The content is brief and primarily serves as a news alert for the filing, with a focus on market data and other news. Citius Oncology Inc. (CTOR) …

Citius Oncology appoints Jonathan Peri to board of directors By Investing.com

Citius Oncology, Inc. has appointed Jonathan Peri, Ph.D., J.D., as an independent director to its board, expanding it to nine members. Peri brings 30 years of experience in higher education, financial services, law, and corporate governance. The company, a subsidiary of Citius Pharmaceuticals, Inc., …

New Citius Oncology director brings college, legal and bank experience